Drug intelligence / Profile preview

se-ethyl-isoselenourea

Development stage: Unknown
Modality: Small Molecules

Overview

Se-Ethyl-Isoselenourea is a synthetic organoselenium compound classified as a selenoether. It is an experimental small molecule that acts as an inhibitor of nitric oxide synthase 3 (endothelial NOS, eNOS). The compound has been studied for its ability to bind and inhibit the active site of eNOS, potentially through hydrogen bonding and nonpolar van der Waals interactions. This mechanism suggests possible applications in modulating nitric oxide production and related vascular or inflammatory processes. Se-Ethyl-Isoselenourea has also been investigated in structural biology studies to map enzyme-inhibitor interactions[1][2][4]. There are no approved clinical indications or marketed formulations.

Other names: (ethylselanyl)methanimidamideethyl imidoselenocarbamateethyl carbamimidoselenoate

Targets

NOS3 (eNOS)

Beyond the preview

Go deeper on se-ethyl-isoselenourea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on se-ethyl-isoselenourea.

Explore the full profile